Influence of inhaled bacteriophage therapy on oral mucosal immunity in children with acute tonsillitis

Cover Page

Cite item

Full Text

Abstract

The study aimed to assess the effect of inhaled bacteriophage therapy on oral mucosal immunity in children with acute tonsillitis.

 Materials and methods. We examined 212 patients aged 4 to 15 years old with acute tonsillitis and 110 age-matched apparently healthy children. Research methods: calculating the Neutrophil to lymphocyte ratio (NLR), saliva diagnostics — secretory immunoglobulin A (sIgA) and the pro-inflammatory cytokine (TNFα). Taking into account the scheme of the treatment, the patients were divided into mutually comparable groups: the first group included patients with acute tonsillitis who received the standard generally accepted treatment depending on the clinical form of the pathology, without using bacteriophage therapy — n = 107 (50.5%), the second group — patients receiving a course of bacteriophage therapy — n = 105 (49.95%), nebulizer bacteriophage therapy using liquid complex pyobacteriophage (PCL) (Microgen, Russia) from the first days of the disease along with standard treatment. Results. During bacteriophage therapy, on the 6th day of treatment, an increased sIgA level up to 97.2% was observed particularly in younger and adolescent patients up to 97.2% (p ≤ 0.05). At the same time, this parameter reached 75.8% and 81.6%, respectively (p ≤ 0.05), in patients who received only standard treatment. The following difference between the two study groups was observed: between patients in the younger age subgroup — 21.4%, in the older age subgroup -16.1% (p ≤ 0.05 relative to control group), which indicates a more effective drug-related effect in patients from the younger age group groups. Similar changes are observed while analyzing level of the pro-inflammatory cytokine (TNFα).

 Conclusion. The use of inhaled bacteriophage therapy in the combination treatment of children with acute tonsillitis helps to shorten the period of general and local clinical manifestations of the disease by 1.4-fold and improve mean local immunity from 5.7% up to 16.1% (p ≤ 0.05).

About the authors

Shokhida T. Turdieva

Tashkent Pediatric Medical Institute

Author for correspondence.
Email: Shohidahon69@mail.ru
ORCID iD: 0000-0001-7042-5387
SPIN-code: 5520-6507
Scopus Author ID: 57204178033
ResearcherId: L-6078-2018

DSc (Medicine), Associate Professor, Department of Family Medicine No. 1

Uzbekistan, Tashkent

Durdona K. Ganieva

Tashkent Pediatric Medical Institute

Email: durdona.ganieva.63@mail.ru
ORCID iD: 0000-0001-5262-4091
Scopus Author ID: 57224069034
ResearcherId: ABG-8082-2021

Assistant Professor, Department of Family Medicine No. 1

Uzbekistan, Tashkent

Gulmira R. Nasirova

Tashkent Pediatric Medical Institute

Email: gulmira_nasirova79@mail.ru
ORCID iD: 0000-0001-5638-8305
Scopus Author ID: 57261417400

Assistant Professor, Department of Family Medicine No. 1

Uzbekistan, Tashkent

References

  1. Алексанина Н.В., Моисеева О.В. Экспериментальное изучение эффективности совместного лечебного действия лактоглобулина и бактериофага сальмонеллезного // Инфекция и иммунитет. 2017. Т. 7, № 3. C. 297–302. [Aleksanina N.V., Moiseyeva O.V. Experimental study of the effectiveness of the joint therapeutic action of lactoglobulin and Salmonella bacteriophage. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2017, vol. 7, no. 3, pp. 297–302. (In Russ.)] doi: 10.15789/2220-7619-2017-3-297-302
  2. Арзуманян В.Г., Колыганова Т.И., Свитич О.А., Самойликов П.В., Конаныхина С.Ю., Зайцева Т.А., Зверев В.В. Вклад лактоферрина, сывороточного альбумина и секреторного иммуноглобулина класса А в антимикробную активность сыворотки грудного молока // Инфекция и иммунитет. 2022. Т. 12, № 3. C. 519–526. [Arzumanian V.G., Kolyganova T.I., Svitich O.A., Samoilikov P.V., Konanykhina S.Yu., Zaytseva T.A., Zverev V.V. An impact of lactoferrin, serum albumin and secretory immunoglobulin A in actimicrobial activity of breast milk whey. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2022, vol. 12, no. 3, pp. 519–526. (In Russ.)] doi: 10.15789/2220-7619-GPO-1759
  3. Гаделия М.В. Применение бактериофагов при хроническом тонзиллите // Международный научно-исследовательский журнал. 2021. Т. 111, № 9. C. 12–17. [Gadeliya M.V. The use of bacteriophages in chronic tonsillitis. Mezhdunarodnyi nauchno-issledovatel’skii zhurnal = International Research Journal, 2021, vol. 111, no. 9, pp. 12–17. (In Russ.)] doi: 10.23670/IRJ.2021.9.111.036
  4. Захарова И.Н., Геппе Н.А., Сугян Н.Г., Денисова А.Р., Бережная И.В. Топические этиотропные препараты в терапии инфекционно-воспалительных заболеваний глотки у детей дошкольного возраста. Результаты многоцентрового рандомизированного клинического исследования. // Российская оториноларингология. 2021. Т. 20, № 1. С. 102–117. [Zakharova I.N., Geppe N.A., Sugyan N.G., Denisova A.R., Berezhnaya I.V. Topical etiotropic drugs in therapy of infectious inflammatory diseases of pharynx in preschool children. Results of multicenter randomized comparative clinical trial. Rossiiskaya otorinolaringologiya = Russian Otorhinolaryngology, 2021, vol. 20, no. 1, pp. 102–117. (In Russ.)] doi: 10.18692/1810-4800-2021-1-102-117
  5. Никифорова Г.Н., Пшонкина Д.М. Возможности использования бактериофагов в лечении инфекционных заболеваний ЛОР-органов у детей // Медицинский Совет. 2015. № 6. C. 34–37. [Nikiforova G.N., Pshonkina D.M. The potential of bacteriophages in the treatment of ENT infections in children. Meditsinskiy sovet = Medical Council, 2015, no. 6, pp. 34–37. (In Russ.)] doi: 10.21518/2079-701X-2015-6-34-37
  6. Свистушкин В.М., Мокоян Ж.Т., Карпова О.Ю. Возможности эффективной топической монотерапии пациентов с острым тонзиллофарингитом // Consilium Medicum. 2018. № 11. C. 8–12. [Svistushkin V.M., Mokoyan Zh.T., Karpova O.Yu. Potential of effective topic monotherapyin patients with acute tonsillopharyngitis. Consilium Medicum, 2018, vol. 20, no. 11, pp. 8–12. (In Russ.)] doi: 10.26442/20751753.2018.11.180067
  7. Семанин А.Г., Садртдинова Г.Р. Выбор оптимального метода выделения бактериофагов бактерий рода Flavobacterium // Инфекция и иммунитет. 2019. Т. 9, № 2. C. 399–403. [Semanin A.G., Sadrtdinova G.R. Choosing a proper approach for isolating bacteriophages specific to Flavobacterium genus bacteria. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2019, vol. 9, no. 2, pp. 399–403. (In Russ.)] doi: 10.15789/2220-7619-2019-2-399-403
  8. Турдиева Ш.Т., Насирова Г.Р., Ганиева Д.К. Возможности ингаляционной бактериофаготерапии при лечении детей с острым тонзиллитом // Медицинский Совет. 2021. № 17. С. 86–93. [Turdieva S.T., Nasirova G.R., Ganiyeva D.K. Possibilities of inhalation bacteriophage therapy in treatment of children with acute tonsillitis. Meditsinskiy sovet = Medical Council, 2021, no. 17, pp. 86–93. (In Russ.)] doi: 10.21518/2079-701X-2021-17-86-93
  9. Brandtzaeg P. Secretory IgA: designed for anti-microbial defense. Front. Immunol., 2013, vol. 6, no. 4: 222. doi: 0.3389/fimmu.2013.00222
  10. Lönnqvist E., Gröndahl-Yli-Hannuksela K., Loimaranta V., Vuopio J. Low rate of asymptomatic carriage and salivary immunoglobulin A response to group A Streptococci in the healthy adult population in Finland. Med. Microbiol. Immunol., 2022, vol. 211, no. 5–6, pp. 261–267. doi: 10.1007/s00430-022-00750-9
  11. Menon K., McNally J.D., Choong K., Lawson M.L., Ramsay T., Hutchison J.S., Foster J., Wong H.R.; Canadian Critical Care Trials Group STRIPES Investigators. A cohort study of pediatric shock: frequency of corticosteriod use and association with clinical Outcomes. Shock, 2015, vol. 44, no. 5, pp. 402–409. doi: 10.1097/SHK.0000000000000355
  12. Sarmiento Varón L., De Rosa J., Rodriguez R., Fernández P.M., Billordo L.A., Baz P., Beccaglia G., Spada N., Mendoza F.T., Barberis C.M., Vay C., Arabolaza M.E., Paoli B., Arana E.I. Role of tonsillar chronic inflammation and commensal bacteria in the pathogenesis of pediatric OSA. Front. Immunol., 2021, vol. 12: 648064. doi: 10.3389/fimmu.2021.648064
  13. Sweere J.M., Van Belleghem J.D., Ishak H., Bach M.S., Popescu M., Sunkari V., Kaber G., Manasherob R., Suh G.A., Cao X., de Vries C.R., Lam D.N., Marshall P.L., Birukova M., Katznelson E., Lazzareschi D.V., Balaji S., Keswani S.G., Hawn T.R., Secor P.R., Bollyky P.L. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science, 2019, vol. 6434, no. 363: eaat9691. doi: 10.1126/science.aat9691
  14. Turdieva S.T., Nasirova G.R. Oral microbiota in children with acute tonsillitis. Biomed. Biotechnol. Res. J., 2021, no. 5, pp. 272–275. doi: 10.4103/bbrj.bbrj_84_21
  15. Tetz G., Tetz V. Bacteriophage infections of microbiota can lead to leaky gut in an experimental rodent model. Gut. Pathog., 2016, no.8: 33. doi: 10.1186/s13099-016-0109-1
  16. Tzira D., Prezerakou A., Papadatos I., Vintila A., Bartzeliotou A., Apostolakou F., Papassotiriou I., Papaevangelou V. Salivary biomarkers may measure stress responses in critically ill children. SAGE Open Med., 2018, vol. 6: 2050312118802452. doi: 10.1177/ 2050312118802452
  17. Yoon S.S., Moon E.Y. B cell adhesion to fibroblast-like synoviocytes is up-regulated by tumor necrosis factor-alpha via expression of human vascular cell adhesion molecule-1 mediated by B cell-activating factor. Int. J. Mol. Sci., 2021, vol. 22, no. 13: 7166. doi: 10.3390/ijms22137166

Copyright (c) 2023 Turdieva S.T., Ganieva D.K., Ramziddinovna G.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies